Neural Therapeutics Inc.

As of January 31, 2026, Neural Therapeutics Inc. carries a market capitalization of 3.37M, placing it among publicly traded companies globally. Its enterprise value stands at 3.31M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of January 31, 2026, Neural Therapeutics Inc. has 168.70M shares outstanding.

These figures are as of January 31, 2026.

As of January 31, 2026, Neural Therapeutics Inc. maintains a current ratio of 0.39, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended January 31, 2026. Return on assets (ROA) is negative at -114.98, reflecting losses generated across the asset base.

As of the close on October 15, 2026, Neural Therapeutics Inc.'s stock has gained approximately 0.00% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.02.

Over the twelve months ended January 31, 2026, Neural Therapeutics Inc. generated - - in revenue and converted that into -1.26M in net income, yielding earnings per share of -0.01. EBITDA reached -994,264.00, while operating income came in at -969,874.00.

These figures are as of January 31, 2026. Total book value stands at 653,224.00, with working capital of -111,526.00 providing operational flexibility.

Neural Therapeutics Inc. produced -409,471.00 in operating cash flow over the twelve months ended January 31, 2026.

These figures cover the twelve months ended January 31, 2026. Free cash flow yield is negative at -16.96: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

As of January 31, 2026, Neural Therapeutics Inc. has an Altman Z-Score of -4.77, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.